Literature DB >> 1329996

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group.

P L Horn-Ross1, A S Whittemore, R Harris, J Itnyre.   

Abstract

Nonepithelial ovarian cancers are rare, and little is known about their etiology. Of particular interest are the effects of oral contraceptive use and pregnancy, both of which are associated with large decreases in risk for epithelial ovarian cancer. We examined the risk factors for nonepithelial ovarian tumors by combining data from four case-control studies conducted in the United States. We compared personal characteristics of 38 germ cell cases and 45 stromal cases, respectively, with 1,142 and 2,617 general population controls. All subjects were over age 18 years. For germ cell tumors, there was a weak negative association with parity but no consistent pattern of decreasing risk with increasing parity. In contrast, relative to nulligravid women, gravid nulliparous women were at increased risk of developing a germ cell cancer [odds ratio (OR) = 4.8, 95% confidence interval (CI) = 1.2-18.6]. The use of oral contraceptives was also associated with elevated risk (OR = 2.0, 95% CI = 0.77-5.1); however, no clear trends in risk were observed. For stromal tumors, oral contraceptive use was associated with decreased risk (OR = 0.37, 95% CI = 0.16-0.83), whereas pregnancy was associated with a small elevation in risk. A trend of increasing risk with increasing age at first term pregnancy was observed, with an odds ratio of 3.6 (95% CI = 1.0-12.5) for a first birth after age 29 years. Risk factors for nonepithelial ovarian cancers do not appear to parallel each other or those for epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329996     DOI: 10.1097/00001648-199211000-00005

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  8 in total

1.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 2.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer.

Authors:  Tianhui Chen; Helja-Marja Surcel; Eva Lundin; Marjo Kaasila; Hans-Ake Lakso; Helena Schock; Rudolf Kaaks; Pentti Koskela; Kjell Grankvist; Goran Hallmans; Eero Pukkala; Anne Zeleniuch-Jacquotte; Paolo Toniolo; Matti Lehtinen; Annekatrin Lukanova
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-21       Impact factor: 4.254

Review 4.  Oral contraceptives and cancer: an update.

Authors:  C La Vecchia; A Altieri; S Franceschi; A Tavani
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: a Norwegian prospective study.

Authors:  G Albrektsen; I Heuch; G Kvåle
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Intrauterine factors and risk of nonepithelial ovarian cancers.

Authors:  Weiva Sieh; Kristina Sundquist; Jan Sundquist; Marilyn A Winkleby; Casey Crump
Journal:  Gynecol Oncol       Date:  2014-02-14       Impact factor: 5.482

Review 7.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2013-08-13

Review 8.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.